Press release
Investigation announced for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
An investigation for investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares over potential securities laws violations.
Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Intercept Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
New York based Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Intercept Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $179.8 million in 2018 to $252.00 million in 2019 and that its normalized Loss increased from $309.24 million in 2019 to $344.68 million in 2019.
On October 8, 2020, news outlets reported that Intercept Pharmaceuticals, Inc. was “facing an investigation from the U.S. Food and Drug Administration over the potential risk of liver injury in patients taking Ocaliva, [Intercept’s] treatment for primary biliary cholangitis, a rare, chronic liver disease.”
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) declined from $125.00 per share in late 2019 to as low as $27.83 per share on October 23, 2020.
Those who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) here
News-ID: 2172079 • Views: …
More Releases from Shareholders Foundation
Constellation Brands, Inc. (NYSE: STZ) Investor Alert: Deadline in Lawsuit on Ap …
A deadline is coming up on April 21, 2025 in the lawsuit filed for certain investors of Constellation Brands, Inc. (NYSE: STZ) over alleged securities laws violations by Constellation Brands, Inc.
Investors who purchased shares of Constellation Brands, Inc. (NYSE: STZ) have certain options and there are strict and short deadlines running. Deadline: April 21, 2025. Constellation Brands, Inc. (NYSE: STZ) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Long-Term Investors who hold shares of MGP Ingredien …
An investigation was announced for current long-term investors in shares of MGP Ingredients, Inc. (NASDAQ: MGPI) concerning potential breaches of fiduciary duties by certain directors of MGP Ingredients, Inc.
Investors who are current long term investors in MGP Ingredients, Inc. (NASDAQ: MGPI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Investigation announced for Long-Term Investors in shares of Kyverna Therapeutic …
An investigation was announced for long-term investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) concerning potential breaches of fiduciary duties by certain directors and officers of Kyverna Therapeutics, Inc.
Investors who are current long term investors in Kyverna Therapeutics, Inc. (NASDAQ: KYTX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of Everus Construction Gr …
An investor, who purchased shares of Everus Construction Group, Inc. (NYSE: ECG), filed a lawsuit in the U.S. District Court for the Southern District of New York over alleged violations of Federal Securities Laws by Everus Construction Group, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Everus Construction Group, Inc. (NYSE: ECG) have certain options and for certain investors are short and strict deadlines…
More Releases for Intercept
Ocaliva Market Significantly Stepping towards the Success Till 2027| Intercept P …
Obeticholic acid (OCA) is a semi-synthetic bile acid analogue with the molecular structure 6-ethyl-chenodeoxycholic acid, which is sold under the brand name Ocaliva. It is prescribed for the treatment of primary biliary cholangitis. Outside of Japan and China, where it is licenced to Dainippon Sumitomo Pharma, Intercept Pharmaceuticals Inc. holds the worldwide rights to develop OCA. In 2020, the global Ocaliva market size was US$ XX million and it is…
Investigation announced for Long-Term Investors in Intercept Pharmaceuticals, In …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Intercept Pharmaceuticals, Inc..
Investors who are current long term investors in Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for investors in (NASDAQ: ICPT stocks follows a lawsuit filed against Intercept Pharmaceuticals, Inc. over…
Lawsuit filed for Investors in shares of Intercept Pharmaceuticals, Inc. (NASDAQ …
An investor, who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), filed a lawsuit over alleged violations of Federal Securities Laws by Intercept Pharmaceuticals, Inc.
Investors who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) have certain options and for certain investors are short and strict deadlines running. Deadline: January 4, 2021. NASDAQ: ICPT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
New York based…
Submarine Active Intercept and Ranging System Market to Witness Robust Expansion …
LP INFORMATION offers a latest published report on Submarine Active Intercept and Ranging System Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Submarine Active Intercept and Ranging System market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024,…
Submarine Active Intercept and Ranging System Market Size, Share, Development by …
Global Info Research offers a latest published report on Submarine Active Intercept and Ranging System Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Submarine Active Intercept and Ranging System players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze…
Global Fatty Liver Disease Drug Market 2017 : Intercept Pharmaceuticals, Allerga …
Fatty Liver Disease Drug Market 2017
A market study based on the " Fatty Liver Disease Drug Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Fatty Liver Disease Drug Market 2017’. The research report analyses the historical as well as present performance of the worldwide Fatty Liver Disease Drug industry, and makes predictions on the future status of Fatty Liver Disease Drug market…
